These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32008032)

  • 1. Biologic therapy use and pregnancy outcomes in women with immune-mediated inflammatory rheumatic diseases.
    Brites L; Madeira N; Rodrigues J; Marona J; Martins N; Águeda A; Freitas R; Neto A; Capela S; Sequeira G; Ganhão S; Duarte C; Santiago M; Santos MJ
    Acta Reumatol Port; 2019; 44(4):266-272. PubMed ID: 32008032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers.
    Shimada H; Kameda T; Kanenishi K; Miyatake N; Nakashima S; Wakiya R; Kato M; Miyagi T; Mansour MMF; Hata T; Kadowaki N; Dobashi H
    Clin Rheumatol; 2019 May; 38(5):1453-1458. PubMed ID: 30729372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing pregnancy in inflammatory rheumatological diseases.
    Jain V; Gordon C
    Arthritis Res Ther; 2011 Feb; 13(1):206. PubMed ID: 21371350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation.
    Levy RA; de Jesús GR; de Jesús NR; Klumb EM
    Autoimmun Rev; 2016 Oct; 15(10):955-63. PubMed ID: 27490204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study.
    Andreoli L; Gerardi MC; Gerosa M; Rozza D; Crisafulli F; Erra R; Lini D; Trespidi L; Padovan M; Ruffilli F; Serale F; Cuomo G; Raffeiner B; Semeraro P; Tani C; Chimenti MS; Conigliaro P; Hoxha A; Nalli C; Fredi M; Lazzaroni MG; Filippini M; Taglietti M; Franceschini F; Zatti S; Loardi C; Orabona R; Ramazzotto F; Zanardini C; Fontana G; Gozzoli G; Barison C; Bizioli P; Caporali RF; Carrea G; Ossola MW; Maranini B; Silvagni E; Govoni M; Morano D; Verteramo R; Doria A; Del Ross T; Favaro M; Calligaro A; Tonello M; Larosa M; Zen M; Zambon A; Mosca M; Zucchi D; Elefante E; Gori S; Iannone F; Anelli MG; Lavista M; Abbruzzese A; Fasano CG; D'Angelo S; Cutro MS; Picerno V; Carbone T; Padula AA; Rovere-Querini P; Canti V; De Lorenzo R; Cavallo L; Ramoni V; Montecucco C; Codullo V; Milanesi A; Pazzola G; Comitini G; Marvisi C; Salvarani C; Epis OM; Benedetti S; Di Raimondo G; Gagliardi C; Lomater C; Crepaldi G; Bellis E; Bellisai F; Garcia Gonzalez E; Pata AP; Zerbinati M; Urban ML; Mattioli I; Iuliano A; Sebastiani G; Brucato AL; Bizzi E; Cutolo M; Santo L; Tonetta S; Landolfi G; Carrara G; Bortoluzzi A; Scirè CA; Tincani A;
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38663885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
    Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
    Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-modifying anti-rheumatic drug use in pregnant women with rheumatic diseases: a systematic review of the risk of congenital malformations.
    Baldwin C; Avina-Zubieta A; Rai SK; Carruthers E; De Vera MA
    Clin Exp Rheumatol; 2016; 34(2):172-83. PubMed ID: 26940667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study.
    Weber-Schoendorfer C; Chambers C; Wacker E; Beghin D; Bernard N; ; Shechtman S; Johnson D; Cuppers-Maarschalkerweerd B; Pistelli A; Clementi M; Winterfeld U; Eleftheriou G; Pupco A; Kao K; Malm H; Elefant E; Koren G; Vial T; Ornoy A; Meister R; Schaefer C
    Arthritis Rheumatol; 2014 May; 66(5):1101-10. PubMed ID: 24470106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs.
    Wallenius M; Lie E; Daltveit AK; Salvesen KÅ; Skomsvoll JF; Kalstad S; Lexberg ÅS; Mikkelsen K; Kvien TK; Østensen M
    Arthritis Rheumatol; 2015 Jan; 67(1):296-301. PubMed ID: 25418443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.
    Götestam Skorpen C; Hoeltzenbein M; Tincani A; Fischer-Betz R; Elefant E; Chambers C; da Silva J; Nelson-Piercy C; Cetin I; Costedoat-Chalumeau N; Dolhain R; Förger F; Khamashta M; Ruiz-Irastorza G; Zink A; Vencovsky J; Cutolo M; Caeyers N; Zumbühl C; Østensen M
    Ann Rheum Dis; 2016 May; 75(5):795-810. PubMed ID: 26888948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Fetal safety profile of drugs used in the treatment of inflammatory rheumatic diseases].
    Falcão S; Mourão AF; Pimentão JB; Branco JC
    Acta Reumatol Port; 2007; 32(4):323-31. PubMed ID: 18159198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preconception Counseling.
    Østensen M
    Rheum Dis Clin North Am; 2017 May; 43(2):189-199. PubMed ID: 28390562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of rheumatic diseases during pregnancy.
    Elliott AB; Chakravarty EF
    Postgrad Med; 2010 May; 122(3):213-21. PubMed ID: 20463432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.
    Bérard A; Zhao JP; Shui I; Colilla S
    Ann Rheum Dis; 2018 Apr; 77(4):500-509. PubMed ID: 29222350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perinatal exposure to conventional synthetic disease-modifying anti-rheumatic drugs in women with rheumatic disease and neonatal outcomes: a population-based study.
    Howren A; Rebić N; Sayre EC; Tsao NW; Amiri N; Baldwin C; De Vera MA
    Clin Exp Rheumatol; 2020; 38(6):1080-1087. PubMed ID: 32141437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Rheumatic diseases need more attention in case of the desire to have children and during pregnancy].
    de Man YA; Dolhain RJ; Steegers EA; Hazes JM
    Ned Tijdschr Geneeskd; 2011; 155(13):A2622. PubMed ID: 21447200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary complications of biological therapies in children and adults with rheumatic diseases.
    Nisar MK; Ostör AJ
    Paediatr Respir Rev; 2013 Dec; 14(4):236-41. PubMed ID: 23462434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy.
    Nguyen H; Ahmed K; Luo W; Flint J; Giles I
    Semin Arthritis Rheum; 2021 Dec; 51(6):1205-1217. PubMed ID: 34689007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reuma.pt contribution to the knowledge of immune-mediated systemic rheumatic diseases.
    Santos MJ; Canhão H; Mourão AF; Oliveira Ramos F; Ponte C; Duarte C; Barcelos A; Martins F; Melo Gomes JA
    Acta Reumatol Port; 2017; 42(3):232-239. PubMed ID: 28917219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?
    Ostensen M; Ramsey-Goldman R
    Drug Saf; 1998 Nov; 19(5):389-410. PubMed ID: 9825952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.